Share a complete list of your prescriptions, over-the-counter products, vitamins, and supplements so your clinician can check for interactions and adjust care as needed
Our Philosophy We don't believe in miracle solutions or short-lived trends
53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity 2024-07-17 After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%
See my options Research Snapshot Head-to-head comparison Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages
Contrave may have an edge for emotional or reward-driven eating because it targets brain reward circuits directly
14 July 2026 7 min Microneedling aftercare day by day: the realistic 7-day timeline What to expect after microneedling, day by day, plus the simple aftercare that protects your skin and your results across the first week